NITD008

SKU: orb1706909

Description

NITD008 is a potent and selective adenosine nucleoside analog with broad-spectrum antiviral activity. It has demonstrated inhibitory effects against viruses such as dengue and Zika in both in vitro assays and in vivo animal models, making it a valuable tool for antiviral research.

Research Area

Cell Biology, Infectious Disease & Virology, Molecular Biology

Images & Validation

−

Key Properties

−

CAS Number	1044589-82-3
MW	290.27
Purity	98.04% (May vary between batches)
Formula	C₁₃H₁₄N₄O₄
SMILES	Nc1ncnc2n(ccc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)C#C
Target	Others,Anti-infection,DNA/RNA Synthesis
Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.89 mM);DMSO:50 mg/mL (172.25 mM)

Bioactivity

−

Target IC50	HCV 1b:0.11 μM (EC50)\|DENV-2:0.64 μM (EC50)
In Vivo	NITD008, with good pharmacokinetic properties, is orally bioavailable. The formulation using 6 N HCl (1.5 equimolar amount), 1 N NaOH (pH adjusted to 3.5), and 100 mM citrate buffer (pH 3.5) yields the best pharmacokinetic parameters. Following intravenous (i.v.) injection, NITD008 demonstrates a high volume of distribution (3.71 L/kg) and low systemic clearance (31.11 mL/min per kg), resulting in a long elimination half-life (t1/2=4.99 h). After oral dosing, NITD008 is rapidly absorbed (time of peak plasma concentration=0.5 h), reaching a maximal plasma concentration of 3 μM, with a bioavailability of 48%. When administered immediately after viral infection, a dose of 1 mg/kg of NITD008 does not reduce mortality, but treatment with 3 mg/kg provides partial protection, and doses of ≥10 mg/kg completely protect infected mice from death. NITD008 effectively suppresses peak viremia, reduces cytokine elevation, and prevents mortality in the infected mice. Read more...
In Vitro	NITD008 exhibits potent inhibition against various viruses, including Dengue virus (DENV), West Nile virus, yellow fever virus, and Poissan virus. In the case of DENV-2, NITD008 inhibits the virus in a dose-responsive manner, with an EC50 value of 0.64 μM. Treatment with 9 μM of the compound results in a reduction in viral titer by >104-fold.Furthermore, NITD008 also demonstrates inhibitory activity against a luciferase-reporting replicon of hepatitis C virus (HCV, genotype 1b), a member of the genus Hepacivirus, with an EC50 value of 0.11 μM. Read more...

Storage & Handling

−

Storage	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Dengue Fever virus, DENV-2, Antiviral, Adenosine kinase, 7-Deaza-2'-C-acetylene-adenosine, NITD008, NITD-008, NITD 008

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

44633776 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

NITD008 (orb1706909)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

NITD008

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

NITD008 (orb1706909)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors